CRISPR Therapeutics AG

CRISPR Therapeutics AG is a pioneering biotechnology company dedicated to developing transformative gene-based medicines for serious human diseases. Leveraging its proprietary CRISPR/Cas9 gene-editing platform, the company precisely alters specific sequences of genomic DNA to address the root causes of genetic disorders. CRISPR Therapeutics boasts a robust pipeline spanning multiple therapeutic areas, including hemoglobinopathies, CAR T cell therapies for oncology and autoimmune indications, in vivo gene editing for cardiovascular diseases, and type 1 diabetes. Its lead product candidate, CASGEVY, represents a significant advancement as an ex vivo CRISPR/Cas9 gene-edited cell therapy designed to treat transfusion-dependent beta-thalassemia and severe sickle cell disease by enhancing fetal hemoglobin production. The company is also advancing investigational CAR T programs targeting CD19 and CD70, alongside in vivo gene editing candidates for cardiovascular conditions by disrupting angiopoietin-like protein 3 and lipoprotein. Furthermore, CRISPR Therapeutics is developing an allogeneic, gene-edited stem cell therapy for type 1 diabetes. The company's strategic focus on innovation and its collaborations, notably with Vertex Pharmaceuticals Incorporated, underscore its commitment to translating cutting-edge gene-editing technology into life-changing therapies for patients worldwide.